WO2025096594A3 - Cellules exprimant des récepteurs antigéniques chimériques anti-cd19 et leurs procédés d'utilisation - Google Patents

Cellules exprimant des récepteurs antigéniques chimériques anti-cd19 et leurs procédés d'utilisation Download PDF

Info

Publication number
WO2025096594A3
WO2025096594A3 PCT/US2024/053633 US2024053633W WO2025096594A3 WO 2025096594 A3 WO2025096594 A3 WO 2025096594A3 US 2024053633 W US2024053633 W US 2024053633W WO 2025096594 A3 WO2025096594 A3 WO 2025096594A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
chimeric antigen
car
cells expressing
antigen receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/053633
Other languages
English (en)
Other versions
WO2025096594A2 (fr
Inventor
Elvin J. LAURON
Thomas Charles PERTEL
Barbra Johnson SASU
Cesar Adolfo Sommer
Steven W. JIN
Suhasni GOPALAKRISHNAN
Zhe Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allogene Therapeutics Inc
Original Assignee
Allogene Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allogene Therapeutics Inc filed Critical Allogene Therapeutics Inc
Priority to AU2024369584A priority Critical patent/AU2024369584A1/en
Publication of WO2025096594A2 publication Critical patent/WO2025096594A2/fr
Publication of WO2025096594A3 publication Critical patent/WO2025096594A3/fr
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4232—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4251—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/28—Expressing multiple CARs, TCRs or antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/34—Vector systems having a special element relevant for transcription being a transcription initiation element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des constructions d'ADN codant pour un récepteur antigénique chimérique (CAR) spécifique de CD19 et d'autres protéines recombinantes, par exemple, une protéine de liaison à CD70 ou un CAR spécifique de CD70, et des cellules immunitaires modifiées (par exemple, des lymphocytes T CAR spécifiques de CD19 ou des lymphocytes T CAR doubles CD19/CD70) comprenant les constructions d'ADN, leurs procédés de fabrication, et leurs utilisations dans des applications thérapeutiques.
PCT/US2024/053633 2023-10-30 2024-10-30 Cellules exprimant des récepteurs antigéniques chimériques anti-cd19 et leurs procédés d'utilisation Pending WO2025096594A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024369584A AU2024369584A1 (en) 2023-10-30 2024-10-30 Cells expressing anti-cd19 chimeric antigen receptors and methods of use thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202363594261P 2023-10-30 2023-10-30
US63/594,261 2023-10-30
US202463659501P 2024-06-13 2024-06-13
US63/659,501 2024-06-13

Publications (2)

Publication Number Publication Date
WO2025096594A2 WO2025096594A2 (fr) 2025-05-08
WO2025096594A3 true WO2025096594A3 (fr) 2025-06-12

Family

ID=93520627

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/053633 Pending WO2025096594A2 (fr) 2023-10-30 2024-10-30 Cellules exprimant des récepteurs antigéniques chimériques anti-cd19 et leurs procédés d'utilisation

Country Status (2)

Country Link
AU (1) AU2024369584A1 (fr)
WO (1) WO2025096594A2 (fr)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017156484A1 (fr) * 2016-03-11 2017-09-14 Bluebird Bio, Inc. Cellules effectrices immunes éditées par le génome
WO2017180989A2 (fr) * 2016-04-15 2017-10-19 Memorial Sloan Kettering Cancer Center Lymphocyte t transgénique et compositions de lymphocyte t exprimant un récepteur antigénique chimérique et procédés associés
WO2020108643A1 (fr) * 2018-11-30 2020-06-04 Beijing Meikang Geno-Immune Biotechnology Co., Ltd. Immunothérapie par car-t combinée basée sur cd19 et cd70
WO2020180694A1 (fr) * 2019-03-01 2020-09-10 Allogene Therapeutics, Inc. Récepteurs de cytokines chimériques constitutivement actifs
WO2022266203A1 (fr) * 2021-06-15 2022-12-22 Allogene Therapeutics, Inc. Ciblage sélectif de cellules alloréactives de l'hôte cd70 + pour prolongation de la persistance des cellules car-t allogéniques
WO2023170693A1 (fr) * 2022-03-09 2023-09-14 Bar Ilan University Lymphocytes t modifiés métaboliquement, compositions les comprenant et leurs utilisations
WO2023192895A1 (fr) * 2022-03-29 2023-10-05 Allogene Therapeutics Inc. Récepteurs de commutateurs chimériques pour la conversion de signaux immunoréactifs en signaux de costimulation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
KR20030032922A (ko) 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 세포의 동시 자극 및 농축
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9987308B2 (en) 2011-03-23 2018-06-05 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
WO2019178427A1 (fr) 2018-03-14 2019-09-19 Arbor Biotechnologies, Inc. Nouveaux systèmes et enzymes de ciblage d'adn crispr
CN121380024A (zh) 2020-03-31 2026-01-23 阿伯生物技术公司 包含Cas12i2变体多肽的组合物及其用途
US20230193243A1 (en) 2020-05-29 2023-06-22 Arbor Biotechnologies, Inc. Compositions comprising a cas12i2 polypeptide and uses thereof
WO2021257730A2 (fr) 2020-06-16 2021-12-23 Arbor Biotechnologies, Inc. Cellules modifiées par un polypeptide cas12i

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017156484A1 (fr) * 2016-03-11 2017-09-14 Bluebird Bio, Inc. Cellules effectrices immunes éditées par le génome
WO2017180989A2 (fr) * 2016-04-15 2017-10-19 Memorial Sloan Kettering Cancer Center Lymphocyte t transgénique et compositions de lymphocyte t exprimant un récepteur antigénique chimérique et procédés associés
WO2020108643A1 (fr) * 2018-11-30 2020-06-04 Beijing Meikang Geno-Immune Biotechnology Co., Ltd. Immunothérapie par car-t combinée basée sur cd19 et cd70
WO2020180694A1 (fr) * 2019-03-01 2020-09-10 Allogene Therapeutics, Inc. Récepteurs de cytokines chimériques constitutivement actifs
WO2022266203A1 (fr) * 2021-06-15 2022-12-22 Allogene Therapeutics, Inc. Ciblage sélectif de cellules alloréactives de l'hôte cd70 + pour prolongation de la persistance des cellules car-t allogéniques
WO2023170693A1 (fr) * 2022-03-09 2023-09-14 Bar Ilan University Lymphocytes t modifiés métaboliquement, compositions les comprenant et leurs utilisations
WO2023192895A1 (fr) * 2022-03-29 2023-10-05 Allogene Therapeutics Inc. Récepteurs de commutateurs chimériques pour la conversion de signaux immunoréactifs en signaux de costimulation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
M. J. FRIGAULT ET AL: "Identification of Chimeric Antigen Receptors That Mediate Constitutive or Inducible Proliferation of T Cells", CANCER IMMUNOLOGY RESEARCH, vol. 3, no. 4, 19 January 2015 (2015-01-19), US, pages 356 - 367, XP55271039, ISSN: 2326-6066, DOI: 10.1158/2326-6066.CIR-14-0186 *
MOSTI LAURA ET AL: "Targeted multi-epitope switching enables straightforward positive/negative selection of CAR T cells", GENE THERAPY, NATURE PUBLISHING GROUP, LONDON, GB, vol. 28, no. 9, 1 February 2021 (2021-02-01), pages 602 - 612, XP037568533, ISSN: 0969-7128, [retrieved on 20210201], DOI: 10.1038/S41434-021-00220-6 *
PANOWSKI SILER H. ET AL: "Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma", CANCER RESEARCH, vol. 82, no. 14, 18 July 2022 (2022-07-18), pages 2610 - 2624, XP055967258, ISSN: 0008-5472, Retrieved from the Internet <URL:https://aacrjournals.org/cancerres/article-pdf/82/14/2610/3179894/2610.pdf> DOI: 10.1158/0008-5472.CAN-21-2931 *

Also Published As

Publication number Publication date
AU2024369584A1 (en) 2026-04-09
WO2025096594A2 (fr) 2025-05-08

Similar Documents

Publication Publication Date Title
AU2016238583B2 (en) Chimeric antigen receptor
MX2022011411A (es) Proteinas de union a antigeno que se unen especificamente a mage-a.
US20170073415A1 (en) Novel multispecific molecules and novel treatment methods based on such multispecific molecules
JP2014503198A5 (fr)
JP2018523484A (ja) 細胞
WO2024047558A3 (fr) Protéines de liaison à l&#39;antigène et récepteurs antigéniques chimériques spécifiques pour le domaine 9 de cd307e humain
WO2022024024A3 (fr) Protéines comprenant des domaines de liaison à l&#39;antigène hla-g et leurs utilisations
EP3472205A1 (fr) Récepteur chimérique d&#39;antigène
AU2014393729A1 (en) Novel multispecific molecules and novel treatment methods based on such multispecific molecules
JP2020522267A (ja) 少なくともｃｄ３及びｈｓａを標的とするヘテロ二量体多重特異性抗体フォーマット
EP1589109A3 (fr) Séquences de Borrelia pathogènes semblables à une pmv
JP2005523681A5 (fr)
WO2024151737A3 (fr) Constructions d&#39;anticorps spécifiques de cd19 et compositions associées
WO2025096594A3 (fr) Cellules exprimant des récepteurs antigéniques chimériques anti-cd19 et leurs procédés d&#39;utilisation
WO2023193003A3 (fr) Constructions d&#39;anticorps spécifiques de cd4 et compositions et utilisations associées
WO2025010378A3 (fr) Protéines qui se lient à sp17 comprenant des anticorps anti-sp17 entièrement humains
WO2004058181A3 (fr) Sequences d&#39;especes et de souches de borrelia pathogene de type vmp
WO2023172890A3 (fr) Anticorps anti-ilt2 et leurs utilisations
JP4892717B2 (ja) ニワトリキメラ抗体およびその利用
US20220184130A1 (en) Artificial signalling molecule
CN110117325B (zh) 一种猪cd127多肽及其编码基因和应用
WO2024223928A3 (fr) Récepteur antigénique chimérique co-récepteur
WO2000043419A3 (fr) Proteine de voies d&#39;exocytose et leurs procedes d&#39;utilisation
CN100480270C (zh) 一种趋化小肽与双特异抗体的融合蛋白
WO2025122587A3 (fr) Anticorps anti-ly6k et procédés d&#39;utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24805697

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: AU2024369584

Country of ref document: AU

Ref document number: 831486

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 831486

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2024369584

Country of ref document: AU

Date of ref document: 20241030

Kind code of ref document: A